, World Health Organization (WHO), WHO Report on the Global Tobacco Epidemic, 2015.

, Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study, GBD 2015 Risk Factors Collaborators, vol.388, pp.1659-1724, 2015.

K. Wilson, N. Gibson, A. Willan, and D. Cook, Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies, Arch. Intern. Med, vol.160, pp.939-944, 2000.

J. A. Critchley and S. Capewell, Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review, JAMA, vol.290, pp.86-97, 2003.

, Centers for Disease Control and Prevention. Quitting Smoking Among Adults-United States, vol.65, pp.1457-1464, 2000.

C. Jiménez-ruiz, I. Berlin, and T. Hering, Varenicline: a novel pharmacotherapy for smoking cessation, Drugs, vol.69, pp.1319-1357, 2009.

H. J. Aubin, A. Luquiens, and I. Berlin, Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice, Br. J. Clin. Pharmacol, vol.77, pp.324-336, 2014.

C. Chauvet, Statins Reduce the Risks of Relapse to Addiction in Rats, Neuropsychopharmacology, vol.41, pp.1588-1597, 2016.

L. V. Panlilio, Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings, Neuropsychopharmacology, vol.37, pp.1838-1847, 2012.

K. A. Perkins, Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence, Nicotine Tob. Res, vol.18, pp.74-78, 2016.

M. B. Pomrenze, T. L. Fetterly, D. G. Winder, and R. O. Messing, The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?, Alcohol. Clin. Exp. Res, vol.41, 1986.

M. L. Schwandt, The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects, Neuropsychopharmacology, vol.41, pp.2818-2829, 2016.

A. Saheki, T. Terasaki, I. Tamai, and A. Tsuji, In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, Pharm. Res, vol.11, pp.305-311, 1994.

S. Sierra, Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death, J. Alzheimers Dis, vol.23, pp.307-318, 2011.

F. Tison, Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients, Parkinsonism Relat. Disord, vol.19, pp.416-421, 2013.

T. Lancaster and L. F. Stead, Individual behavioural counselling for smoking cessation, Cochrane Database Syst. Rev, vol.3, p.1292, 2017.

L. Siemer, Study protocol for a non-inferiority trial of a blended smoking cessation treatment versus face-to-face treatment (LiveSmokefree-Study), BMC Public Health, vol.16, p.1187, 2016.

M. E. Mooney, Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial, Clin. Pharmacol. Ther, vol.100, pp.344-352, 2016.

K. Cahill, S. Stevens, R. Perera, and T. Lancaster, Pharmacological interventions for smoking cessation: an overview and network meta-analysis, Cochrane Database Syst. Rev, vol.5, p.9329, 2013.

K. Cahill, S. Stevens, and T. Lancaster, Pharmacological treatments for smoking cessation, JAMA, vol.311, pp.193-194, 2014.

A. Matthews, Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data, BMJ, vol.353, p.3283, 2016.

R. Collins, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, vol.388, pp.2532-2561, 2016.

, Institut national de prévention et d' éducation pour la santé. J'arrête de fumer. Le guide pratique pour y parvenir

H. Autorité-de-santé, Arrêt de la consommation de tabac: du dépistage individuel au maintien de l'abstinence en premier recours. Méthode recommandations pour la pratique clinique Argumentaire scientifique, 2013.

T. F. Heatherton, L. T. Kozlowski, R. C. Frecker, and K. O. Fagerström, The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire, Br. J. Addict, vol.86, pp.1119-1127, 1991.

R. L. Richmond, L. A. Kehoe, and I. W. Webster, Multivariate models for predicting abstention following intervention to stop smoking by general practitioners, Addiction, vol.88, pp.1127-1135, 1993.

I. Berlin, E. G. Singleton, and S. J. Heishman, Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers, Nicotine Tob. Res, vol.12, pp.500-507, 2010.

L. F. Stead, Nicotine replacement therapy for smoking cessation, Cochrane Database Syst. Rev, vol.11, p.146, 2012.